Surgical management of giant secondary malignant fibrous histiocytoma following radiotherapy for nasopharyngeal carcinoma: A case report and literature review

Tong,Liping; Wang,Yong; Zhou,Yongan; Zheng,Xiaoqing; Liu,Honggang; Sun,Jianyong; Li,Xiaofei; Yan,Xiaolong

doi:10.3892/ol.2014.2069

Surgical management of giant secondary malignant fibrous histiocytoma following radiotherapy for nasopharyngeal carcinoma: A case report and literature review

Authors:
- Liping Tong
- Yong Wang
- Yongan Zhou
- Xiaoqing Zheng
- Honggang Liu
- Jianyong Sun
- Xiaofei Li
- Xiaolong Yan
View Affiliations

Affiliations: Department of Thoracic Surgery, Tangdu Hospital of the Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of General Surgery, Weinan Center Hospital, Weinan, Shaanxi 714000, P.R. China
Published online on: April 15, 2014 https://doi.org/10.3892/ol.2014.2069
Pages: 72-76

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant fibrous histiocytoma (MFH) is rare in the chest wall, particularly in patients who have undergone radiotherapy for primary nasopharyngeal cancer. In the present study, a case of MFH of the upper chest wall that appeared four years after initial radiotherapy for squamous cell carcinoma of the nasopharynx is reported. Furthermore, two‑step surgical management was successfully performed consisting of i) tumor‑reductive excision and ii) limb salvage surgery, including wide resection of the tumor mass, defect reconstruction of the chest wall using left latissimus dorsi myocutaneous flap and dermatoplasty of the flap‑supplied region. The progress of the clinical characteristics, the reasons for radiation‑induced carcinogenesis, the treatment options and the prognostic factors of MFH are also reviewed. Finally, the importance of prevention and follow‑up of this malignancy are highlighted and specific advice is offered.

View Figures

View References

1	Stadler FJ, Scott GA and Brown MD: Malignant fibrous tumors. Semin Cutan Med Surg. 17:141–152. 1998.
2	Bentz BG, Singh B, Woodruff J, Brennan M, Shah JP and Kraus D: Head and neck soft tissue sarcomas: a multivariate analysis of outcomes. Ann Surg Oncol. 11:619–628. 2004.
3	Peiper M, Zurakowski D, Knoefel WT and Izbicki JR: Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery. 135:59–66. 2004.
4	Ron E: Ionizing radiation and cancer risk: evidence from epidemiology. Radiat Res. 150(5 Suppl): S30–S41. 1998.
5	Riad S, Biau D, Holt GE, Werier J, Turcotte RE, Ferguson PC, Griffin AM, Dickie CI, Chung PW, Catton CN, O’Sullivan B and Wunder JS: The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer. 118:2682–2692. 2012.
6	Teo WY, Tan HK, Goh BC and Putti TC: Postirradiation sarcoma of the sphenoid bone - a case report. Ann Acad Med Singapore. 35:104–107. 2006.
7	Foran P, Colleran G, Madewell J and O’Sullivan PJ: Imaging of thoracic sarcomas of the chest wall, pleura, and lung. Semin Ultrasound CT MR. 32:365–376. 2011.
8	Hartel PH, Bratthauer G, Hartel JV and Fanburg-Smith JC: Primary malignant fibrous histiocytoma (myxofibrosarcoma/pleomorphic sarcoma not otherwise specified) of the breast: clinicopathologic study of 19 cases. Ann Diagn Pathol. 15:407–413. 2011.
9	Al-Agha OM and Igbokwe AA: Malignant fibrous histiocytoma. between the past and present. Arch Pathol Lab Med. 132:1030–1035. 2008.
10	Szollosi Z, Nemeth T, Egervari K and Nemes Z: Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytoma. Pathol Res Pract. 201:369–377. 2005.
11	Cahan WG, Woodward HQ, Higinbotham NL, Stewart FW and Coley BL: Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer. 1:8–34. 1948.
12	Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller T and Shah IC: Radiation-induced sarcoma of bone. Cancer. 28:1087–1099. 1971.
13	Preston D, Shimizu Y, Pierce DA, Suyama A and Mabuchi K: Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950–1997. Radiat Res. 160:381–407. 2003.
14	Mullenders L, Atkinson M, Paretzke H, Sabatier L and Bouffler S: Assessing cancer risks of low-dose radiation. Nat Rev Cancer. 9:596–604. 2009.
15	Krueger SA, Joiner MC, Weinfeld M, Piasentin E and Marples B: Role of apoptosis in low-dose hyper-radiosensitivity. Radiat Res. 167:260–267. 1997.
16	Prise KM and O’Sullivan JM: Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 9:351–360. 2009.
17	Matsumoto S, Ahmed AR, Kawaguchi N, Manabe J and Matsushita Y: Results of surgery for malignant fibrous histiocytomas of soft tissue. Int J Clin Oncol. 8:104–109. 2003.
18	Hoy E, Granick M, Benevenia J, Patterson F, Datiashvili R and Bille B: Reconstruction of musculoskeletal defects following oncologic resection in 76 patients. Ann Plast Surg. 57:190–194. 2003.
19	Issakov J, Kollender Y, Soyfer V, Bickels J, Flusser G, Meller I and Merimsky O: A single-team experience of limb sparing approach in adults with high-grade malignant fibrous histiocytoma. Oncol Rep. 14:1071–1076. 2005.
20	Marchese R, Bufo P, Carrieri G and Bove G: Malignant fibrous histiocytoma of the kidney treated with nephrectomy and adjuvant radiotherapy: a case report. Case Rep Med. 4:8020262010.
21	Clinical Trial Registry. http://clinicaltrials.gov/ct2/show/NCT00400569?term=sunitinib+malignant+fibrous&rank=2. Accessed December 29, 2011
22	Todoroki T, Kondo T, Sugahara S, Morishita Y, Mori K and Ohno T: Long-term survivor of relapsed MFH on the thigh treated with autologous formalin-fixed tumor vaccine (AFTV) combined with limb-sparing surgery and radiotherapy. World J Surg Oncol. 9:962011.
23	NCCN. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma V.2.2007. http://www.globalgist.org/docs/NCCN_guidelines.pdf. Accessed January 23, 2012
24	Henderson MT and Hollmig ST: Malignant fibrous histiocytoma: changing perceptions and management challenges. J Am Acad Dermatol. 67:1335–1341. 2012.